Bedaquiline

British Journal of Clinical Pharmacology

Volumn 80, Issue 2, 2015, Pages 182-184

  Goulooze, Sebastiaan C ^a   Cohen, Adam F ^a,b   Rissmann, Robert ^a,b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bedaquiline; multidrug resistant tuberculosis; therapeutic use

Indexed keywords

BEDAQUILINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTHRALGIA; ARTICLE; DIRECTLY OBSERVED THERAPY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MECHANISM; HUMAN; MEDICATION COMPLIANCE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; PRIORITY JOURNAL; TREATMENT INDICATION; TUBERCULOSIS; VOMITING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; ATP SYNTHETASE COMPLEXES; CLINICAL TRIALS, PHASE II AS TOPIC; DIARYLQUINOLINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84937519070     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12613     Document Type: Article

References (10)

1. European Medicines Agency. Summary of the risk management plan (RMP) for Sirturo (bedaquiline). 2014 Mar 14 [updated 2014 May 6; cited 2014 Dec 18]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Risk-management-plan-summary/human/002614/WC500162201.pdf.
2. Lakshmanan M, Xavier AS,. Bedaquiline-The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013; 5: 112-5.
3. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D,. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One 2011; 6: e23575.
4. Lu P, Lill H, Bald D,. ATP synthase in mycobacteria: special features and implications for a function as drug target. Biochim Biophys Acta 2014; 1837: 1208-18.
5. Matteelli A, Carvalho AC, Dooley KE, Kritski A,. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-58.
6. European Medicines Agency. Sirturo: EPAR-Product Information. 2014 Mar 14 [updated 2014 Jun 2; cited 2014 Dec 18]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002614/WC500163209.pdf.
7. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A, Bald D,. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009; 53: 1290-2.
8. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De MT, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De PE, van Heeswijk RP, Dannemann B,. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-32.
9. Schluger NW,. Diagnosis, treatment, and prevention of drug-resistant tuberculosis. [updated Nov 25 2014; cited Dec 17 2014]. Available at http://www.uptodate.com/contents/diagnosis-treatment-and-prevention-of-drug-resistant-tuberculosis.
10. Cox E, Laessig K,. FDA approval of bedaquiline - the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014; 371: 689-91.